Stock ESF EUROFINS SCIENTIFIC SE
Add to a list
To use this feature you must be a member
Log inSign up

Financials Eurofins Scientific SE Deutsche Boerse AG

Equities

ESF

FR0000038259

Healthcare Facilities & Services

End-of-day quote Deutsche Boerse AG
Other stock markets
 04:30:00 05/02/2024 am IST 		5-day change 1st Jan Change
53.62 EUR -1.07% Intraday chart for Eurofins Scientific SE -4.59% -9.73%
09:13am UK Competition Watchdog Begins Probe of Eurofins' Purchase of Technical Testing, Analysis Business MT
15/07 Eurofins: dispute with SGS over termination of contract CF

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 8,834 13,091 20,893 12,900 11,336 9,315 - -
Enterprise Value (EV) 1 12,079 15,333 23,132 15,739 14,041 12,388 12,356 12,100
P/E ratio 47.2 x 25 x 27.8 x 22.2 x 45.4 x 22.3 x 17.8 x 14.9 x
Yield 0.7% 0.99% 0.92% 1.49% 0.85% 1.24% 1.65% 1.84%
Capitalization / Revenue 1.94 x 2.41 x 3.11 x 1.92 x 1.74 x 1.32 x 1.22 x 1.14 x
EV / Revenue 2.65 x 2.82 x 3.44 x 2.34 x 2.16 x 1.76 x 1.62 x 1.48 x
EV / EBITDA 13 x 10.9 x 12.2 x 10.4 x 10.3 x 8.27 x 7.42 x 6.6 x
EV / FCF 46.8 x 17.6 x 22.8 x 23.2 x 29.6 x 22.6 x 18.7 x 15.8 x
FCF Yield 2.14% 5.69% 4.39% 4.3% 3.38% 4.42% 5.33% 6.33%
Price to Book 3.11 x 3.55 x 4.49 x 2.7 x 2.24 x 1.76 x 1.68 x 1.53 x
Nbr of stocks (in thousands) 1,78,759 1,90,749 1,92,035 1,92,365 1,92,194 1,92,855 - -
Reference price 2 49.42 68.63 108.8 67.06 58.98 48.30 48.30 48.30
Announcement Date 04/03/20 01/03/21 22/02/22 01/03/23 27/02/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 4,563 5,439 6,718 6,712 6,515 7,056 7,612 8,182
EBITDA 1 930.7 1,413 1,902 1,513 1,364 1,499 1,664 1,834
EBIT 1 573.5 1,024 1,473 1,037 842 897.9 1,035 1,167
Operating Margin 12.57% 18.82% 21.93% 15.45% 12.92% 12.72% 13.59% 14.26%
Earnings before Tax (EBT) 1 271.5 694.4 1,057 780 423 548 694.7 832.3
Net income 1 195.2 539.4 783 606 310 415 524.8 628.6
Net margin 4.28% 9.92% 11.66% 9.03% 4.76% 5.88% 6.89% 7.68%
EPS 2 1.047 2.750 3.910 3.020 1.300 2.168 2.708 3.232
Free Cash Flow 1 258 873.2 1,015 677 474.2 547.3 659.1 765.6
FCF margin 5.65% 16.05% 15.11% 10.09% 7.28% 7.76% 8.66% 9.36%
FCF Conversion (EBITDA) 27.72% 61.81% 53.36% 44.75% 34.77% 36.52% 39.6% 41.75%
FCF Conversion (Net income) 132.17% 161.88% 129.63% 111.72% 152.97% 131.89% 125.59% 121.8%
Dividend per Share 2 0.3450 0.6800 1.000 1.000 0.5000 0.5974 0.7986 0.8874
Announcement Date 04/03/20 01/03/21 22/02/22 01/03/23 27/02/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 S2 2023 Q1 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 2,395 2,323 3,116 3,272 1,630 1,816 3,446 1,760 1,652 3,412 1,622 3,300 1,574 3,209 1,611 1,695 3,306 1,653 3,467 3,650 3,741 3,880
EBITDA 515.8 493 919.7 1,008 - - 894 - - 829 - - - 640 - - - - 725 - - -
EBIT 322.7 310.7 - - - - - - - - - - - 397 - - - - - - - -
Operating Margin 13.47% 13.37% - - - - - - - - - - - 12.37% - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - - 220 - - - - - - - -
Net income - - - - - - - - - - - - - 152 - - - - - - - -
Net margin - - - - - - - - - - - - - 4.74% - - - - - - - -
EPS - - - - - - - - - - - - - 0.7600 - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - - - - - - - - -
Announcement Date 04/03/20 06/08/20 01/03/21 05/08/21 21/10/21 22/02/22 22/02/22 21/04/22 27/07/22 27/07/22 18/10/22 01/03/23 26/04/23 26/07/23 24/10/23 27/02/24 27/02/24 24/04/24 - - - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 3,245 2,242 2,239 2,839 2,705 3,073 3,041 2,785
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 3.486 x 1.587 x 1.177 x 1.876 x 1.983 x 2.05 x 1.827 x 1.519 x
Free Cash Flow 1 258 873 1,015 677 474 547 659 766
ROE (net income / shareholders' equity) 7.09% 16.5% 18.8% 12.9% 6.29% 10.2% 11.3% 12.1%
ROA (Net income/ Total Assets) 2.6% 6.58% 8.74% 6.24% 2.96% 3.47% 4.58% 5.56%
Assets 1 7,514 8,199 8,954 9,708 10,486 11,954 11,446 11,314
Book Value Per Share 2 15.90 19.30 24.20 24.80 26.30 27.40 28.70 31.60
Cash Flow per Share 2 3.640 6.250 7.510 5.710 5.140 5.590 6.300 7.120
Capex 1 420 350 495 645 544 608 634 661
Capex / Sales 9.2% 6.44% 7.37% 9.61% 8.34% 8.61% 8.33% 8.08%
Announcement Date 04/03/20 01/03/21 22/02/22 01/03/23 27/02/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Eurofins Scientific SE

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
48.3 EUR
Average target price
59.69 EUR
Spread / Average Target
+23.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+19.32% 84.59B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-21.99% 77.33B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+1.06% 27.12B
LABCORP HOLDINGS INC. Stock Labcorp Holdings Inc.
-5.06% 18.19B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
+7.94% 18.49B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
+7.69% 16.49B
NATERA, INC. Stock Natera, Inc.
+76.20% 13.55B
TENET HEALTHCARE CORPORATION Stock Tenet Healthcare Corporation
+76.56% 13.03B
PURE HEALTH HOLDING Stock Pure Health Holding
-27.72% 12.43B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. ERF Stock
  4. ESF Stock
  5. Financials Eurofins Scientific SE